A5017181765- MicroRNA in disease regulation
- Epigenetics and DNA Methylation
- Bioinformatics and Genomic Networks
- Chronic Lymphocytic Leukemia Research
- Glioma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Radiomics and Machine Learning in Medical Imaging
- HER2/EGFR in Cancer Research
- Acute Myeloid Leukemia Research
- Advanced Breast Cancer Therapies
- Childhood Cancer Survivors' Quality of Life
- Cancer Genomics and Diagnostics
- Immunodeficiency and Autoimmune Disorders
- Lung Cancer Treatments and Mutations
- Cancer Risks and Factors
- Reproductive Biology and Fertility
- Diversity and Career in Medicine
- Brain Metastases and Treatment
- Advances in Oncology and Radiotherapy
- Monoclonal and Polyclonal Antibodies Research
- Neuroblastoma Research and Treatments
- Neutropenia and Cancer Infections
- Eosinophilic Disorders and Syndromes
Royal Hobart Hospital
2016-2025
University of Tasmania
2017-2024
Princess Margaret Cancer Centre
2019
Australia New Zealand Gynaecological Oncology Group
2015
North West Regional Hospital
2015
Peter MacCallum Cancer Centre
2015
American Society of Clinical Oncology
2015
Launceston General Hospital
2015
Flinders Medical Centre
2015
Australasian Leukaemia and Lymphoma Group
2011
The prognosis for patients with acute promyelocytic leukemia (APL) has improved dramatically since the introduction of all-trans retinoic acid (ATRA) and intravenous arsenic trioxide (ATO). However, ATO administration requires daily infusions over several months, representing an onerous burden hospitals patients. We evaluated bioavailability a novel encapsulated oral formulation in APL first complete remission during standard-of-care consolidation. After pilot study exploring likely dose...
Abstract Anemia is the predominant cytopenia in myelodysplastic syndromes (MDS) and treatment options are limited. Roxadustat a hypoxia‐inducible factor prolyl hydroxylase inhibitor approved for of anemia chronic kidney disease UK, EU, China, Japan, South Korea, Chile. MATTERHORN phase 3, randomized, double‐blind, placebo‐controlled study to assess efficacy safety roxadustat lower risk‐MDS. Eligible patients had baseline serum erythropoietin ≤ 400 mIU/mL, low packed RBC transfusion burden....
Abstract In patients with lower‐risk myelodysplastic syndromes/neoplasms (MDS), response to first‐line therapy is limited and transient. The MATTERHORN randomized, double‐blind, phase 3 trial evaluated roxadustat versus placebo for transfusion‐dependent, MDS. Eligible had very low‐, or intermediate‐risk MDS without prior erythropoiesis‐stimulating agent treatment, a transfusion burden of 1–4 packed red blood cell (pRBC) units every 8 weeks (Q8W). Patients were randomized (3:2) oral (2.5...
Background: The Phase 3 MURANO trial (NCT02005471) reported superior progression-free survival (PFS) and overall (OS) with fixed-duration VenR vs bendamustine (B)R in patients (pts) R/R CLL. At the 5-year update, median (m)PFS was 53.6 17.0 months (P<0.0001), OS rates were 82.1% 62.2% (P<0.0001) pts treated BR, respectively (Seymour et al. Blood 2022). Aims: We report final analyses of MURANO, 7 years follow-up (FU): specifically, updated PFS OS, minimal residual disease (MRD) evaluation,...
Purpose: This study investigated the impact of fertility-related discussions on Adolescent and Young Adult (AYA) cancer patients' quality life (QoL) factors influencing provision these discussions.Methods: Recruitment was conducted through population-based state registries. Eligible AYAs were 15–24 years at diagnosis, 3–24 months postdiagnosis, with any (except early stage melanoma). As part a larger survey, asked about their experiences QoL (FACT-G).Results: Of 207 returning surveys (29%...
Introduction: Fixed-duration (FD) VenR treatment (tx) in patients (pts) with R/R CLL the Phase 3 MURANO trial (NCT02005471) resulted superior progression-free survival (PFS) and overall (OS), versus bendamustine (B)R. This was sustained at 5 years (y) median (m) follow up (FU): PFS, 53.6 months [mo] 17.0 mo BR; y OS rates, 82.1% 62.2% p < 0.0001 for both. We report final analyses of 7 mFU: specifically, updated PFS OS, minimal residual disease (MRD) evaluation, pts treated main study,...
Dasatinib has shown superiority over imatinib in achieving molecular responses (MRs) chronic phase myeloid leukemia but with a different toxicity profile, which may impact its overall benefit. Reported toxicities include pleural effusions and pulmonary hypertension, although the incidence of these events is well described, response to therapy dose modifications on not been comprehensively characterized real-world setting. We retrospectively reviewed dasatinib adverse 212 patients at 17...
Fixed-duration venetoclax-rituximab (VenR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) the phase 3 MURANO trial (NCT02005471) resulted superior progression-free survival (PFS) and overall (OS) vs bendamustine-rituximab (BR). We report final analyses of (median 7 years follow-up). Patients were randomized to VenR (venetoclax 400 mg daily for 2 plus monthly rituximab 6 months; n = 194) or BR (6 195). In a substudy, progressive disease (PD) received as retreatment...
<p>Supplementary Figure S1 is a stylised illustration of DEPTH’s use sliding windows to identify genomic susceptibility regions.</p>
<p>Supplementary Figure S2 shows the estimation of genetic ancestry AGOG, GliomaScan and GICC samples by way scatter plot PC1 versus PC2.</p>
Background/Aim The aim of this study was to describe the time and documentation needed gain ethics governance approvals in Australian states with without a centralised ethical review system. Methods This is prospective descriptive undertaken between February 2012 March 2015. Paediatric adult hospitals ( n = 67) were approached allow their medical records. Participants included 15‐ 24‐year‐olds diagnosed cancer 2008 2012. main outcomes measures (weeks) approval for number type documents...